LEARN THE FACTS AND
MOST FREQUENT QUESTIONS ABOUT I.P.T.
I. What is IPT?
II. How does it work?
III. Scientific explanation
IV. Who administers these treatments?
V. What types of cancer does IPT treat?
I.
IPT stands for Insulin Potentiation Therapy,
discovered by Dr. Donato Perez Garcia in Mexico City, 1930. It is a patented
medical protocol used to treat cancer with less dosage of chemotherapy, using
insulin as a natural potentiator that targets only cancer cells, reducing
chemotherapy’s toxic side effects, adding natural and biologic medicine to help
restore the body’s natural defenses. It has been developed and researched for
over 80 years; today it is administered by the grandson of the founder, also
named Donato Perez Garcia, M.D.
IPT, subsequently
developed in Insulin Potentiation Targeted Low Dose (IPTLD), is a treatment
that has cured cancer patients, of all types and stages, around the world.
There are more than 451 doctors practicing this protocol in more than 31
countries worldwide.
II.
Let’s define cancer as a loss of harmony and complete disorder of
normal physical and chemical functioning in the body, activated by a cancer
genic agent.
It all starts with
insulin; a hormone produced in the pancreas that regulates metabolism of
carbohydrates, fat and excess glucose from the blood. But it has many more
functions on a cellular level. With
a single shot, Insulin Potentiation Therapy uses insulin to modify cancer cells
molecular biology, inducing a controlled state of hypoglycemia. And because a
cancer cells contains 10 times more insulin receptors than healthy cells,
insulin can help target the medication only to cancer cells. Once it has
reached them, insulin promotes the permeabilization of the cell’s membrane.
Only a trained IPT medical physician will know the exact timing when this
happens, also known as “The Therapeutic Moment”, that’s when all chemotherapy
drugs are administered thru I.V. in far less amounts into the patient. Insulin
Potentiation Targeted Therapy changes the bio-physic-chemical
constants and parameters of the blood, attacking first the cancerous cell
through its intra-extra cellular environment, permeabilizing the cell’s
membrane. This permeabilization assures that anticancer medication will
effectively enter the damaged cells and eventually kill them, reducing the
affected cancer tissue.
The administration of
chemo is so effective that IPT only uses less than half the dosage of what
you’d receive in a traditional chemotherapy session. This will dramatically
reduce your level of toxicity (cause by chemotherapy’s strong medication), with
hardly any side effects, giving you more energy and vitality to fight the
disease and live a healthy life.
As part of an IPT
treatment, you will also receive a detoxification protocol of biologic
medicine, essential nutrients and immune boosters that will fortified your
white cells, helping your own body defend itself against any cancer agent.
Healthy cells remain intact, thus promoting a better quality of life, while
fighting the disease. It is a potent, effective treatment for cancer, in a
gentler, kinder way that wont damage or exert your body. It is the next
generation for administering chemotherapy.
III.
Insulin Potentiation Therapy + Targeted Low Dose (IPTLD ®) manipulates the
mechanisms of malignancy to therapeutic advantage by employing insulin as a
biologic response modifier of cancer cells endogenous molecular biology. The
autonomous proliferation of malignancy is supported by autocrine secretion of
insulin for glucose/energy uptake by cancer cells, and a similar autocrine
and/or paracrine elaboration of cellular factors to stimulate cancer growth.
Amongst these, the insulin-like growth factors have been identified as the most
potent mitogens for cancer cells.
Of primary importance for
IPTLD ®, cancer cell membranes also have six times more insulin receptors and
ten times more IGF receptors, per cell, than the membranes of host normal
tissues. Further, insulin can cross-react with and activate cancer cell IGF
receptors. Thus, per cell, cancer has sixteen times more insulin-sensitive
receptors than normal tissues. As ligand effect is a function of receptor
concentration, these facts serve to differentiate cancer from normal cells - a
vital consideration for the safety of cancer chemotherapy. In light of these
revelations, exogenous insulin acts to enhance anticancer drug cytotoxicity,
and safety, via:
1) A membrane permeability
effect to increase the intracellular dose intensity of the drugs;
2) An effect of metabolic
modification to increase the S-phase fraction in cancer cells, enhancing their
susceptibility to cell-cycle phase-specific agents, and;
3) An effect of
biochemical differentiation based on insulin receptor concentration that
focuses the first two insulin effects predominantly on cancer cells, sparing
host normal tissues.
Significantly fewer drugs
can thus be targeted more specifically and more effectively to cancer cell
populations that are more susceptible to the chemotherapy drug effects, all
this occurring with a virtual elimination of the dose-related side effects of
these powerful drugs.
Because of this favorable
decrease of side effects, cycles of low-dose chemotherapy with IPTLD ® may be
done more frequently. There is good patient acceptance of the hypoglycemic side
effect of insulin in this protocol, and the "rescue phenomenon"
occasioned by the timely administration of hypertonic glucose actually serves
to provide patients with an experiential metaphor for the rapid recovery of
their well being. It is acknowledged that cancer treatment can often be
debilitating for patients. In those undergoing treatment with IPTLD ®, an
overall gentler experience promotes their concurrent use of other important
elements in a program of Comprehensive Cancer Care.
IV.
The most experienced IPT Medical Doctor is Donato Perez Garcia. He is the 3rd
generation of IPT physicians, all of the same name. In 1982 he began working with his
father, Donato Pérez García Bellón, where he learned the therapy discovered by
his grandfather. Together they attended several conferences within the Mexican
republic, then the United States and Europe.
In February of 2001, he
conducted the first IPT training seminar in the city of Las Vegas, where 21
doctors from the United States and Canada attended. During the following years
he dedicated himself in introducing the treatment in Mexico, South America,
Europe, Asia and North Africa, training physicians that offer IPT as an option
for treating cancer and other degenerative diseases. Since then, he’s continued
with annual seminars, attended by international doctors and presentations on
IPTLD® to the United States government organization NIH/NCI/OCCAM.
In 2002 he held the first
IPT Non-Profit Congress, where physicians could exchange scientific knowledge. Few
years ago, he was invited to open an office in the Medical Consultation Tower
in Hospital Angeles de Tijuana. During this period he started making changes to
the treatment administration protocol, now formally called Insulin Potentiation
Targeted Low Dose (IPTLD). He currently practices medicine in Hospital Angeles
in Tijuana, Baja California, Mexico. On January of 2013 he was promoted for a three-year
period as Medical Advisory in Research for the Health Committee of LXII
Legislature. Chamber of Deputies. United States of Mexico. Government of
Mexico.
Has over 30 years
experience in IPT. Has applied over 26,000 treatments to patients worldwide.
V.
The most common are:
* Breast
* Lung
* Ovarian
* Uterine
* Prostate
* Bone
* Lymphoma
* Cervix
* Melanoma
* Renal Cell
* Fibro sarcoma
* Hodgkin's
* Leukemia
Comments
Post a Comment